STE

STERIS plc · NYSE · Healthcare · USD · 10-K for 2026, filed 2026-05-29

Figures on this page computed 2026-11-08 12:24 UTC

Last close

247.91USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2026, filed 2026-05-29

31.7xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
- computed
- 10-K for 2026, filed 2026-05-29
The filing itself
9.3%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
- 10-K for 2026, filed 2026-05-29
- 10-K for 2026, filed 2026-05-29
- 10-K for 2026, filed 2026-05-29
- 10-Q for 2026, filed 2026-08-07
- 10-K for 2026, filed 2026-05-29
- 10-Q for 2026, filed 2026-08-07
The filing itself
13.2%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
- 10-K for 2026, filed 2026-05-29
- 10-K for 2026, filed 2026-05-29
The filing itself
16.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
- 10-K for 2026, filed 2026-05-29
- 10-K for 2026, filed 2026-05-29
The filing itself
0.29Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
- 10-K for 2026, filed 2026-05-29
- 10-Q for 2026, filed 2026-08-07
The filing itself
1.0%Dividend yield
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
- computed
- computed
- computed
- computed
- Computed from the filing for 2026, filed 2026-05-29

Price is the furthest below its sector's middle: 0.31 against 0.36 on the market's range.

Against its rival

lens 4 of 9

Measure by measure

behind on 3 of 4

Profit on each unit of sales13.2%17.9%Behind
Higher is better here.
Return on the capital it uses9.4%n/an/a
Higher is better here.
Sales growth over five years13.8%19.3%Behind
Higher is better here.
Debt against equity0.29n/an/a
Lower is better here.
Gross margin44.3%60.1%Behind
Higher is better here.
Price against earnings31.7x37.1xAhead
Lower is better here.

The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.

Against DexCom, Inc., STE is behind on 3 of 4 measures.

Every figure in this lens

Except where said otherwise: 10-K for 2026, filed 2026-05-29

Profit on each unit of sales13.2%
Source
filed
Statement
income
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
The filing itself
Return on the capital it uses9.3%
Source
filed
Statement
income
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
The filing itself
Sales growth over five years13.8%
Source
filed
Statement
income
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
The filing itself
Debt against equity0.29
Source
filed
Statement
income
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
The filing itself
Gross margin44.3%
Source
filed
Statement
income
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
The filing itself
Price against earnings31.7x
Source
filed
Statement
income
Fiscal year
2026
Accession
0001628280-26-039136
Reported in
USD
The filing itself